Latest News from: Roswell Park Comprehensive Cancer Center

Add to Favorites Subscribe Share
newswise-fb-share-

Showing results

110 of 323
Newswise: Roswell Park Secures More Than $15.4 Million in New Funding for Cancer Research

Article ID: 717425

Roswell Park Secures More Than $15.4 Million in New Funding for Cancer Research

Roswell Park Comprehensive Cancer Center

Roswell Park researchers have received recent grant awards totaling more than $15.4 million. These competitive awards include the first National Institutes of Health funding to study a new electronic tobacco device and a state grant supporting Roswell Park's work with the national Cancer Moonshot.

Released:
13-Aug-2019 4:55 PM EDT
Newswise: Roswell Park Researchers Identify Immune Biomarker of Response in Patients With Advanced Liver Cancer

Article ID: 717421

Roswell Park Researchers Identify Immune Biomarker of Response in Patients With Advanced Liver Cancer

Roswell Park Comprehensive Cancer Center

Roswell Park researchers have uncovered a biomarker that may help explain why some patients respond better than others to sorafenib, a chemotherapy commonly prescribed for patients with advanced liver cancer.

Released:
13-Aug-2019 4:45 PM EDT
Newswise: Roswell Park Team Develops New Method of Tracking Cellular Changes Associated with Cancer

Article ID: 716823

Roswell Park Team Develops New Method of Tracking Cellular Changes Associated with Cancer

Roswell Park Comprehensive Cancer Center

Researchers from Roswell Park have developed a new bioinformatics-based approach for monitoring key changes in cancer cells — a data-driven method that might help to enhance and personalize cancer treatment.

Released:
1-Aug-2019 2:05 PM EDT
Newswise: Immunotherapy-Chemo Combo Based on Work 
of Roswell Park’s Dr. Ben Seon Gets FDA Approval

Article ID: 714657

Immunotherapy-Chemo Combo Based on Work of Roswell Park’s Dr. Ben Seon Gets FDA Approval

Roswell Park Comprehensive Cancer Center

A cancer therapy based on the work of Ben Seon, PhD, at Roswell Park Comprehensive Cancer Center has been approved by the U.S. Food and Drug Administration (FDA) for patients with an aggressive form of non-Hodgkin lymphoma.

Released:
19-Jun-2019 6:05 PM EDT
Newswise: Roswell Park Physician Leads Development of New Multiple Myeloma Imaging Guidelines

Article ID: 714361

Roswell Park Physician Leads Development of New Multiple Myeloma Imaging Guidelines

Roswell Park Comprehensive Cancer Center

Jens Hillengass, MD, Chief of Myeloma at Roswell Park Comprehensive Cancer Center, led an International Myeloma Working Group (IMWG) effort to compile new recommendations for imaging techniques that offer more sensitive and accurate diagnosis and monitoring for patients with multiple myeloma and other plasma-cell disorders.

Released:
13-Jun-2019 2:05 PM EDT
Newswise: ASCO 2019: Favorable Response for Brain Cancer Patients Receiving Combination Therapy With SurVaxM

Article ID: 713799

ASCO 2019: Favorable Response for Brain Cancer Patients Receiving Combination Therapy With SurVaxM

Roswell Park Comprehensive Cancer Center

With their phase II study in patients with aggressive brain cancer now completed, the developers of the cancer immunotherapy SurVaxM report that combination therapy with the vaccine was more effective than standard therapy for nearly all patients.

Released:
3-Jun-2019 4:50 AM EDT
Newswise: Patients’ Own Cells Do the Work in Roswell Park Immunotherapy Study Incorporating Adult Stem Cells

Article ID: 712819

Patients’ Own Cells Do the Work in Roswell Park Immunotherapy Study Incorporating Adult Stem Cells

Roswell Park Comprehensive Cancer Center

A clinical trial underway at Roswell Park Comprehensive Cancer Center will assess a brand-new immunotherapy approach — reprogramming a patient’s blood stem cells to generate a lasting supply of two types of immune cells — in patients with recurrent cancer of the ovaries, fallopian tubes or peritoneum.

Released:
14-May-2019 10:05 AM EDT
Newswise: Researchers Uncover New Role for Tamoxifen in Triple-Negative Breast Cancers

Article ID: 711418

Researchers Uncover New Role for Tamoxifen in Triple-Negative Breast Cancers

Roswell Park Comprehensive Cancer Center

In a new article in JNCI reporting the first known prognostic marker for triple-negative breast cancer, researchers provide evidence that a widely used breast cancer drug, tamoxifen, may be effective against this notoriously aggressive disease subtype.

Released:
16-Apr-2019 11:05 AM EDT
Roswell Logo 2018_RGB.jpg

Article ID: 710507

Use of Oral Contraceptives Protects Against Most-Fatal Types of Ovarian Cancer

Roswell Park Comprehensive Cancer Center

A team from Roswell Park Comprehensive Cancer Center and the University at Buffalo reports that the protective benefit of oral contraceptives is most pronounced with the most aggressive and fatal subtypes of ovarian cancer.

Released:
1-Apr-2019 4:05 AM EDT
Newswise: All in the Timing: Hour of Radiation Treatments Can Affect Mucositis for Patients With Head/Neck Cancers

Article ID: 710513

All in the Timing: Hour of Radiation Treatments Can Affect Mucositis for Patients With Head/Neck Cancers

Roswell Park Comprehensive Cancer Center

New research from Roswell Park Comprehensive Cancer Center reports that timing of radiation treatments can significantly reduce severity of mucositis and its related impacts.

Released:
1-Apr-2019 4:05 AM EDT

Showing results

110 of 323

Chat now!